[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:liposarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":92,"states":97},"Liposarcoma",13,10,[8,16,23,29,36,42,48,54,60,66,72,79,85],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04031677","Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma",[12],"Phase 3","RECRUITING","2026-08-26T02:17:02.694423Z","2026-05-05T02:43:28.835529Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06957431","Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma",[20],"Phase 1","2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.742384Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06474676","T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced\u002FMetastatic Soft Tissue and Bone Sarcoma Patients.",[20],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.639815Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06541262","Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",[33],"2026-08-26T02:16:21.385056Z","2026-07-05T03:45:20.453347Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06198296","Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",[20],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:29.711287Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07148050","Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.698343Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06823167","A Phase 1 Study of IM-1021 in Participants With Advanced Cancer",[20],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.816261Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06881992","A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.217045Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors",[20],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:27.425045Z",{"nct_id":73,"title":74,"phases":75,"status":76,"updated_at":77,"content_modified":78},"NCT07224568","Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:26.899812Z",{"nct_id":80,"title":81,"phases":82,"status":76,"updated_at":83,"content_modified":84},"NCT06039046","Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients",[],"2026-08-26T02:17:00.709807Z","2026-05-13T02:55:06.402708Z",{"nct_id":86,"title":87,"phases":88,"status":89,"updated_at":90,"content_modified":91},"NCT06414434","BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:38:13.938630Z","2026-05-05T02:43:27.915820Z",[93],{"biomarker":94,"count":95,"slug":96},"Glypican-3",4,"glypican-3",[98,102,105,108,111,114,117,121,124,127,130,133,136,139],{"state":99,"count":100,"slug":101},"Texas",7,"texas",{"state":103,"count":95,"slug":104},"California","california",{"state":106,"count":95,"slug":107},"Massachusetts","massachusetts",{"state":109,"count":95,"slug":110},"Missouri","missouri",{"state":112,"count":95,"slug":113},"Ohio","ohio",{"state":115,"count":95,"slug":116},"Tennessee","tennessee",{"state":118,"count":119,"slug":120},"Connecticut",3,"connecticut",{"state":122,"count":119,"slug":123},"Florida","florida",{"state":125,"count":119,"slug":126},"Georgia","georgia",{"state":128,"count":119,"slug":129},"Illinois","illinois",{"state":131,"count":119,"slug":132},"Kentucky","kentucky",{"state":134,"count":119,"slug":135},"Rhode Island","rhode-island",{"state":137,"count":119,"slug":138},"Virginia","virginia",{"state":140,"count":119,"slug":141},"Washington","washington"]